ArcticZymes Technologies ASA's (OB:AZT) Intrinsic Value Is Potentially 43% Above Its Share Price
Feb 15
Have your own idea? Try our Stock Screener
Norwegian (OSEAX) Biotech Industry Analysis
UpdatedFeb 15, 2025
DataAggregated Company Financials
Companies11
- 7D-1.2%
- 3M25.9%
- 1Y-55.1%
- YTD1.8%
Over the last 7 days, the Biotech industry has dropped 2.2%, driven by a pullback from Hofseth BioCare of 9.2%. On the other hand ArcticZymes Technologies is actually up 36%. However, the industry is down 57% over the past year. Earnings are forecast to grow by 27% annually.
Industry Valuation and Performance
Has the Norwegian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 16 Feb 2025 | NOK 5.2b | NOK 453.9m | -NOK 1,113,359,722.34 | 128.2x | -4.7x | 11.5x |
| Tue, 14 Jan 2025 | NOK 4.6b | NOK 458.1m | -NOK 1,078,188,031.28 | 152.5x | -4.2x | 10x |
| Thu, 12 Dec 2024 | NOK 4.4b | NOK 456.7m | -NOK 1,065,579,069.04 | 149x | -4.1x | 9.5x |
| Sat, 09 Nov 2024 | NOK 3.6b | NOK 465.4m | -NOK 1,050,099,650.90 | 100.2x | -3.4x | 7.7x |
| Mon, 07 Oct 2024 | NOK 5.0b | NOK 470.1m | -NOK 1,059,165,831.85 | 58.9x | -4.7x | 10.7x |
| Wed, 04 Sep 2024 | NOK 5.7b | NOK 471.9m | -NOK 1,038,534,117.65 | 62.5x | -5.5x | 12x |
| Fri, 02 Aug 2024 | NOK 9.3b | NOK 517.2m | -NOK 1,053,979,939.68 | 75.5x | -8.8x | 17.9x |
| Sun, 30 Jun 2024 | NOK 9.3b | NOK 642.1m | -NOK 942,827,734.59 | 37.2x | -9.9x | 14.5x |
| Tue, 28 May 2024 | NOK 9.0b | NOK 629.4m | -NOK 972,960,408.48 | 38.1x | -9.2x | 14.3x |
| Thu, 25 Apr 2024 | NOK 8.7b | NOK 659.9m | -NOK 961,366,474.10 | 37.1x | -9x | 13.1x |
| Sat, 23 Mar 2024 | NOK 9.1b | NOK 657.2m | -NOK 940,732,224.70 | 38.1x | -9.6x | 13.8x |
| Mon, 19 Feb 2024 | NOK 15.1b | NOK 671.9m | -NOK 1,003,515,434.30 | 37.4x | -15.1x | 22.5x |
| Wed, 17 Jan 2024 | NOK 16.8b | NOK 656.8m | -NOK 1,359,931,347.00 | 58.7x | -12.4x | 25.6x |
| Fri, 15 Dec 2023 | NOK 15.9b | NOK 656.6m | -NOK 1,359,602,735.00 | 60.3x | -11.7x | 24.3x |
| Sun, 12 Nov 2023 | NOK 14.1b | NOK 642.4m | -NOK 1,464,352,948.00 | 56.5x | -9.7x | 22x |
| Tue, 10 Oct 2023 | NOK 14.7b | NOK 625.5m | -NOK 1,458,651,115.00 | 50.3x | -10.1x | 23.6x |
| Thu, 07 Sep 2023 | NOK 15.6b | NOK 627.1m | -NOK 1,429,546,125.00 | 58.6x | -10.9x | 24.9x |
| Sat, 05 Aug 2023 | NOK 16.4b | NOK 554.5m | -NOK 1,449,376,434.00 | 55.5x | -11.3x | 29.6x |
| Mon, 03 Jul 2023 | NOK 15.1b | NOK 561.6m | -NOK 1,478,500,076.00 | 60.8x | -10.2x | 27x |
| Wed, 31 May 2023 | NOK 16.9b | NOK 565.7m | -NOK 1,509,054,866.00 | 61.5x | -11.2x | 29.9x |
| Fri, 28 Apr 2023 | NOK 16.4b | NOK 541.3m | -NOK 1,443,716,642.00 | 30x | -11.3x | 30.2x |
| Sun, 26 Mar 2023 | NOK 15.0b | NOK 536.5m | -NOK 1,556,728,452.00 | 29.3x | -9.7x | 28x |
| Tue, 21 Feb 2023 | NOK 18.5b | NOK 825.4m | -NOK 1,433,656,572.00 | 32.7x | -12.9x | 22.4x |
| Thu, 19 Jan 2023 | NOK 18.4b | NOK 807.8m | -NOK 1,393,647,595.00 | 25.3x | -13.2x | 22.8x |
| Sat, 17 Dec 2022 | NOK 20.6b | NOK 808.9m | -NOK 1,394,235,100.00 | 41.7x | -14.8x | 25.5x |
| Mon, 14 Nov 2022 | NOK 18.7b | NOK 808.9m | -NOK 1,355,620,015.00 | 36.2x | -13.8x | 23.1x |
| Wed, 12 Oct 2022 | NOK 17.0b | NOK 817.8m | -NOK 1,366,092,570.00 | 36.6x | -12.4x | 20.8x |
| Fri, 09 Sep 2022 | NOK 20.1b | NOK 794.0m | -NOK 1,367,555,311.00 | 37.4x | -14.7x | 25.3x |
| Sun, 07 Aug 2022 | NOK 21.9b | NOK 768.5m | -NOK 1,380,701,299.00 | 45.9x | -15.8x | 28.5x |
| Tue, 05 Jul 2022 | NOK 19.2b | NOK 768.9m | -NOK 1,380,816,704.00 | 42.9x | -13.9x | 25x |
| Thu, 02 Jun 2022 | NOK 22.4b | NOK 1.1b | -NOK 1,030,883,576.00 | 39.8x | -21.7x | 20.6x |
| Sat, 30 Apr 2022 | NOK 24.5b | NOK 1.1b | -NOK 989,576,266.00 | 45.9x | -24.8x | 23x |
| Mon, 28 Mar 2022 | NOK 26.5b | NOK 2.6b | NOK 374.4m | 10x | 70.8x | 10.1x |
| Wed, 23 Feb 2022 | NOK 26.1b | NOK 2.7b | NOK 434.6m | 9.8x | 60.1x | 9.7x |
Price to Earnings Ratio
60.1x
Current Industry PE
- Investors are pessimistic on the Norwegian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 20.5x is higher than the industry's current PS ratio of 11.2x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 45% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the Norwegian Healthcare industry?
| NO Market | -0.26% | |
| Healthcare | 0.94% | |
| Biotech | -1.15% | |
| Biotech | -1.15% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AZT ArcticZymes Technologies | NOK 19.00 | 35.7% +NOK 255.4m | -29.0% | PE128.2x | |
| PCIB PCI Biotech Holding | NOK 1.33 | 7.8% +NOK 3.6m | -30.8% | PS8.3x | |
| ULTI Ultimovacs | NOK 2.10 | 0.5% +NOK 344.1k | -98.5% | PB0.9x |